Navigation Links
MiMedx Announces 2012 Results
Date:3/7/2013

business, and the expected quarterly revenue growth. These statements are based on current information and belief, and are not guarantees of future performance.  Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include that the direct sales force strategy will not continue to produce quarter-over-quarter sales growth, that the clinical study results will not be as positive as anticipated or will not enable the Company to capture additional market presence, that a new patent will not issue in the near term  or that the claims, if any, allowed will be substantially reduced, that competitors can "design around" the Company's patents; that the Company may not be successful in entering into new placenta recovery contracts, that the Company's existing and future placental recovery contracts will not be sufficient to meet the Company's demand for tissue,  that the reimbursement coverage in the Medicare and commercial sectors does not materialize or expands at a rate slower than anticipated, that VA and government business will not continue to increase, that quarterly revenue growth will be below expectations, and the risk factors detailed from time to time in the Company's periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2011. By making these forward-looking statements, the Company does not undertake to update them in any manner except as may be required by the Company's disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws.

 MIMEDX GROUP, INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF OPERATIONS Years Ended December 31,REVENUES:20122011Net sales$
27,053,773$
7,760,446OPERATING COSTS AND EXPENSES:Cost of products sold

5,188,3783,357,909Research and development expenses

'/>"/>
SOURCE MiMedx Group, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. MiMedx Group to Present at the 6th Annual OneMedForum
2. MiMedx Group to Present at the Stifel Nicolaus 2012 Healthcare Conference
3. CCS Medical Announces Agreement with LifeScan
4. HUYA Bioscience Announces Partnership With Shanghai Zhangjiang Biotech Pharmaceutical Base
5. AVANIR PHARMACEUTICALS ANNOUNCES RESEARCH COLLABORATION WITH DEPARTMENT OF VETERANS AFFAIRS FOR SCREENING PSEUDOBULBAR AFFECT (PBA) SYMPTOMS IN VETERANS WITH TRAUMATIC BRAIN INJURY
6. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Impax Laboratories Inc.
7. Sangamo BioSciences Announces Presentation At The Barclays Global Healthcare Conference
8. DMH International Announces The Launch of TouchPACS
9. Psyche Systems Announces Availability of Toxicology LIS
10. Jazz Pharmaceuticals Announces Pricing Of Public Offering Of Ordinary Shares By Selling Shareholders
11. DDS Lab Announces Strategic Alliance with United Concordia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Zafgen, Inc., a leading biopharmaceutical company dedicated ... patients, today announced initial results from its Phase ... methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi ...  These results showed improvements in body weight, hunger-related ...
(Date:1/14/2014)... Mass. , Jan. 14, 2014 HeartWare ... leading innovator of less invasive, miniaturized circulatory support technologies ... today announced that it expects revenues for the fourth ... expected full-year 2013 revenues to approximately $208 million. ...
(Date:1/14/2014)... N.J. , Jan. 14, 2014 InformEx, ... and sellers of high-value chemistry, will hold the 30 th ... Miami Beach Convention Center from January 21-24. ... 3,500 attendees from top pharmaceutical, fine chemical and specialty chemical ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
(Date:4/17/2014)... PLOS Pathogens , children who live in regions of ... immune response to infection with malaria parasites that may ... and illness and partially control the growth of malaria ... develop future interventions that prevent or mitigate the disease ... 200 million cases of malaria occur worldwide, resulting in ...
(Date:4/17/2014)... Two recent papers by a University of Colorado ... scientists develop treatments or vaccines for Dengue fever, ... other disease-causing flaviviruses. , Jeffrey S. Kieft, PhD, ... the School of Medicine and an early career ... colleagues recently published articles in the scholarly journals ...
(Date:4/17/2014)... biology team has created a new technology for ... could travel the body and selectively target cancer ... biological devices that monitor and modify human physiology ... However, no existing technology enabled bioengineers to build ... and respond in a customized fashion. , "The ...
(Date:4/17/2014)... estimated that as many as 10 million older Americans ... loneliness and isolation. , However, new research a ... older Americans for six years found that Internet ... depression by more than 30 percent. , "That,s a ... University professor of telecommunication, information studies and media who ...
(Date:4/17/2014)... 17, 2014 By discovering a new mechanism that ... stroke, researchers at UC Irvine and the Salk Institute ... limit or prevent stroke-induced brain damage. , A complex ... of death and primary reason for disability in the ... stroke and lets blood-borne material into the brain, causing ...
Breaking Medicine News(10 mins):Health News:Study sheds light on how the immune system protects children from malaria 2Health News:CU researchers discover target for treating dengue fever 2Health News:Building 'smart' cell-based therapies 2Health News:Internet use can help ward off depression among elderly 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2
... It was reported on the 30th May that one adult and ... Authorities of NHS Lanarkshire issued a statement confirming that there have ... Law, in South Lanarkshire. All of these cases have a link ... NHS announced that as there was no conclusive evidence yet that ...
... are significantly more likely to experience difficulties during childbirth //and ... of the gruesome practice, a new United Nations study has ... evidence of the harmful effects for women and children, calls ... women worldwide., ,The serious complications during childbirth it cites ...
... day after he was admitted in a private hospital here ... leader Pramod Mahajan // , today showed signs of improvement ... definite improvement in his conditon. His oxygen level and blood ... Rahul was admitted yesterday in the wee hours., ,The ...
... has provided succour to a couple by facilitating kidney donation ... produce a marriage certificate as required by the hospital//. ... Bombay Hospital to relax its rules and allow Chandrabhan Rangari ... ,Chandrabhan could not donate an organ to Sushila, ...
... Fertilisers and Steel Ramvilas Paswan announced that central government ... in order to promote and encourage studies and research ... that his ministry would set up four new institutes ... Education and Research (NIPER) in Hajipur in Bihar, Kolkata ...
... and more Indian students in Qatar, especially Doha, are ... secondary examinations//. ,After clearing their Central Board of ... making a beeline for the various distance education programmes ... ,The Indira Gandhi National Open University ...
Cached Medicine News:Health News:Diagnosis On a Fourth Patient Confirmed To Be E.Coli 2Health News:Indian Students in Qatar Opts For Distance Education 2
Used to establish and maintain nephrostomy drainage following pyeloplasty. Supplied sterile in peel-open packages. Intended for one-time use. CAUTION: Periodic evaluation is advised; stent must not r...
... urinary diversion and drainage. The stylet is ... sheath is left in place to ease ... the access sheath is removed and discarded. ... for external catheter retention. Supplied sterile in ...
... for percutaneous placement of a ... pelvis for nephrostomy drainage in ... sterile in peel-open packages. Intended ... evaluation is advised; catheter must ...
... contains primers, a FAM-labeled probe and an Alexa ... 115 bp region of the 5' UTR. This ... Alexa 532 and Texas Red reporter dyes like ... Reagent* (ASR) program is comprised of a series ...
Medicine Products: